Carmot - About the company
Carmot is an acquired company based in Berkeley (United States), founded in 2008 by Stig Hansen and Daniel Erlanson. It operates as a Developer of disease-modifying therapies to treat metabolic diseases. Carmot has raised $386M in funding from investors like The Column Group, Horizons Ventures and Amgen, with last known valuation of $*****. The company has 420 active competitors, including 164 funded and 67 that have exited. Its top competitors include companies like Sana Biotechnology, Adocia and Kailera.
Company Details
Developer of disease-modifying therapies to treat metabolic diseases. The company is pioneering a drug discovery platform, to identify novel incretin receptor signaling targets to develop a broad pipeline of therapeutics for metabolic diseases including obesity and diabetes. The company has three clinical candidates including CT-388, CT-868, and CT-996.
- Website
- www.carmot.us
- Email ID
- *****@carmot.us
- Phone Number
- +1 **********
Key Metrics
Founded Year
2008
Location
Berkeley, United States
Stage
Acquired
Total Funding
$386M in 16 rounds
Latest Funding Round
Last Known Valuation
$***** as on May 25, 2023
Investors
Ranked
52nd among 420 active competitors
Employee Count
4 as on Sep 30, 2026
Similar Companies
Exit Details
Acquired by Roche (Dec 04, 2023)
Legal entities associated with Carmot
Carmot is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Carmot Therapeutics Inc CIN: 261872684 , United States, Active | - | 2 (As on Dec 31, 2024) | - |
Carmot's acquisition details
Click here to take a look at Carmot's acquisition in detail
Sign up to download Carmot's company profile
Carmot's funding and investors
Carmot has raised a total funding of $386M over 16 rounds. Its first funding round was on Oct 22, 2009. Its latest funding round was a Series E round on May 25, 2023 for $*****. 13 investors participated in its latest round. Carmot has 18 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of Carmot:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 25, 2023 | 1300087 | Series E | 9824545 | 6285251 | 3529322 | 7875267 |
Jul 26, 2022 | 5553161 | Series D | 9186090 | 4608824 | 4150911 | |
Sep 30, 2020 | 3834003 | Series C | 4171100 | 3474363 |
View details of Carmot's funding rounds and investors
Carmot's founders and board of directors
Founder? Claim ProfileHere are the details of Carmot's key team members:
- Stig Hansen: Former Co-Founder & CEO of Carmot and founder of 1 other company. Contact Info: 1 email address
- Daniel Erlanson: Former Co-Founder of Carmot.
- Heather Turner: CEO of Carmot.
View details of Carmot's Founder profiles and Board Members
Carmot's employee count trend
Carmot has 4 employees as of Sep 26. Here is Carmot's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Carmot's Competitors and alternates
Top competitors of Carmot include Sana Biotechnology, Adocia and Kailera. Here is the list of Top 10 competitors of Carmot, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
2nd | Developer of therapeutics for the treatment of diabetes and obesity | $26M | 69/100 | ||
3rd | Kailera 2024, Waltham (United States), Public | Developer of therapies for treating obesity and related conditions | $1B | 65/100 | |
4th | Structure 2017, San Francisco (United States), Public | Developer of oral small molecule drugs for chronic diseases | $191M | 65/100 | |
5th | Assembly Biosciences 2005, New York City (United States), Public | Developing novel antivirals to treat serious viral diseases | $700K | 65/100 | |
6th | Cellino 2017, Cambridge (United States), Series A | Developer of autologous cell therapies | $125M | 65/100 | |
7th | Quell 2019, London (United Kingdom), Series B | Developer of engineered regulatory T cell therapies for immune diseases | $344M | 64/100 | |
8th | Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public | Developer of small molecule drugs for diffrent health diseases | - | 64/100 | |
9th | Rezolute 2012, Denver (United States), Public | Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI) | - | 64/100 | |
10th | Kriya Therapeutics 2012, Redwood City (United States), Series D | Developer of therapeutic solutions for the treatment of diabetes | $938M | 64/100 | |
52nd | Carmot 2008, Berkeley (United States), Acquired | Developer of disease-modifying therapies to treat metabolic diseases | $386M | 59/100 |
Looking for more details on Carmot's competitors? Click here to see the top ones
Carmot's Investments and acquisitions
Carmot has made no investments or acquisitions yet.
Reports related to Carmot
Here is the latest report on Carmot's sector:
News related to Carmot
Media has covered Carmot for a total of 5 events in the last 1 year, 4 of them have been about company updates.
•
Genentech: Press Releases | Genentech Announces Manufacturing Expansion in Hillsboro, OregonGenentech•Aug 20, 2026•Carmot
•
•
•
•
•
•
Roche sees Carmot obesity drugs' potential peak sales at $3.6B+Seeking Alpha•Sep 30, 2024•Roche, Carmot
•
•
Roche to Accelerate Development of Obesity Assets from $2.7B Carmot BuyBioSpace•Jul 26, 2024•Roche, Carmot
•
Roche details early obesity data from GLP-1/GIP agonist, plans for Phase 2 study this yearEndPoints News•Jul 16, 2024•Roche, Carmot
Are you a Founder ?
FAQs about Carmot
Explore our recently published companies
- Himsons - Vadodara based, 1988 founded, Unfunded company
- Com2uS Platform Corp - Unfunded company
- Just Print - Unfunded company